Ticagrelor no better than aspirin for stroke patients
medwireNews: The direct platelet inhibitor ticagrelor has proved no more effective than aspirin for preventing recurrent events in patients who start treatment within 24 hours of noncardioembolic, nonsevere stroke or high-risk transient ischaemic attack (TIA).
The primary endpoint of the multinational randomised SOCRATES trial was myocardial infarction, stroke or death within 90 days. This occurred in 6.7% of 6589 patients given ticagrelor (180 mg loading dose, then 90 mg twice daily) and in 7.5% of 6610 patients given aspirin (300 mg, then 150 mg twice daily), giving a nonsignificant hazard ratio of 0.89 (confidence interval 0.78–1.01; p=0.07).
The safety profiles of the antiplatelet agents were similar, although there was more dyspnoea and minor bleeding with ticagrelor, leading to a higher rate of discontinuation, report S Claiborne Johnston (University of Texas at Austin, USA) and co-investigators in The New England Journal of Medicine. The team presented the findings today at the European Stroke Organisation conference in Barcelona, Spain.
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016